{"classes":[{"categories":[{"measurements":[{"comment":"Only 1 observation was equal or above lower limit of quantification (LLoQ). Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG000","spread":"NA","value":"9.510"},{"groupId":"OG001","spread":"540","value":"5.532"},{"groupId":"OG002","spread":"19873078","value":"16.24"},{"groupId":"OG003","spread":"162","value":"64.96"},{"groupId":"OG004","spread":"190","value":"93.02"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG005","spread":"NA","value":"NA"},{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG006","spread":"NA","value":"9.440"},{"groupId":"OG007","spread":"80","value":"3.082"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG009","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"11"}],"units":"Participants"}],"title":"Cycle 1/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"106","value":"22.13"},{"groupId":"OG001","spread":"135","value":"17.85"},{"groupId":"OG002","spread":"102","value":"19.92"},{"groupId":"OG003","spread":"138","value":"22.02"},{"groupId":"OG004","spread":"74","value":"23.03"},{"groupId":"OG005","spread":"38","value":"25.53"},{"groupId":"OG006","spread":"53","value":"18.37"},{"groupId":"OG007","spread":"45","value":"13.15"},{"groupId":"OG009","spread":"84","value":"9.781"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"17"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"11"}],"units":"Participants"}],"title":"Cycle 1/Day15-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"84","value":"23.14"},{"groupId":"OG001","spread":"115","value":"20.69"},{"groupId":"OG002","spread":"105","value":"22.67"},{"groupId":"OG003","spread":"224","value":"25.45"},{"groupId":"OG004","spread":"77","value":"23.35"},{"groupId":"OG005","spread":"43","value":"27.94"},{"groupId":"OG006","spread":"76","value":"21.61"},{"groupId":"OG007","spread":"80","value":"12.52"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG008","spread":"NA","value":"NA"},{"groupId":"OG009","spread":"110","value":"10.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"17"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"}],"units":"Participants"}],"title":"Cycle 2/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"132","value":"18.79"},{"groupId":"OG001","spread":"103","value":"21.53"},{"groupId":"OG002","spread":"74","value":"32.46"},{"groupId":"OG003","spread":"259","value":"49.20"},{"groupId":"OG004","spread":"59","value":"23.30"},{"groupId":"OG005","spread":"55","value":"26.82"},{"groupId":"OG006","spread":"86","value":"20.21"},{"groupId":"OG007","spread":"85","value":"26.50"},{"groupId":"OG008","spread":"140","value":"10.52"},{"groupId":"OG009","spread":"81","value":"15.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"8"},{"groupId":"OG009","value":"6"}],"units":"Participants"}],"title":"Cycle 4/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"52","value":"24.80"},{"groupId":"OG001","spread":"99","value":"27.33"},{"groupId":"OG002","spread":"40","value":"33.45"},{"groupId":"OG003","spread":"105","value":"59.47"},{"groupId":"OG004","spread":"65","value":"24.28"},{"groupId":"OG005","spread":"57","value":"26.17"},{"groupId":"OG006","spread":"9","value":"20.66"},{"groupId":"OG007","spread":"73","value":"27.62"},{"groupId":"OG008","spread":"43","value":"22.16"},{"groupId":"OG009","spread":"45","value":"21.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"6"}],"units":"Participants"}],"title":"Cycle 6/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46","value":"27.56"},{"groupId":"OG001","spread":"100","value":"26.87"},{"groupId":"OG002","spread":"66","value":"40.42"},{"groupId":"OG003","spread":"24","value":"39.89"},{"groupId":"OG004","spread":"52","value":"34.09"},{"groupId":"OG005","spread":"101","value":"25.31"},{"groupId":"OG007","spread":"47","value":"34.90"},{"groupId":"OG008","spread":"117","value":"19.04"},{"groupId":"OG009","spread":"24","value":"19.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"}],"units":"Participants"}],"title":"Cycle 10/Day1-0 Hour"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"11"}],"units":"Participants"}],"description":"Ctrough is steady-state pre-dose concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"During phase 1b participants with Non-Small Cell Lung Cancer (NSCLC) received utomilumab 500 mg intravenously (IV) every 4 weeks (Q4W) with 10 milligrams per kilogram (mg/kg) of avelumab administered IV every 2 weeks (Q2W) for 2 cycles, where each cycle was of 4 weeks.","id":"OG000","title":"Combination A Phase 1b NSCLC: Utomilumab 500 mg + Avelumab"},{"description":"During phase 1b participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG001","title":"Combination A Phase 1b NSCLC: Utomilumab 100 mg + Avelumab"},{"description":"During phase 1b participants with NSCLC received utomilumab 20 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG002","title":"Combination A Phase 1b NSCLC: Utomilumab 20 mg + Avelumab"},{"description":"During Phase 2 participants with melanoma received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG003","title":"Combination A Phase 2 Melanoma: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Squamous Cell Carcinoma of the Head and Neck (SCCHN) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG004","title":"Combination A Phase 2 SCCHN: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Triple Negative Breast Cancer (TNBC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG005","title":"Combination A Phase 2 TNBC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Squamous cell lung cancer (SCLC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG006","title":"Combination A Phase 2 SCLC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG007","title":"Combination A Phase 2 First Line (1L) NSCLC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W for cycle 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.","id":"OG008","title":"Combination A Phase 2 1L NSCLC: Utomilumab Then Utomilumab + Avelumab"},{"description":"During Phase 2 participants with NSCLC received avelumab 10 mg/kg administered IV Q2W for cycles 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.","id":"OG009","title":"Combination A Phase 2 1L NSCLC: Avelumab Then Utomilumab + Avelumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who received at least one dose of study drug and who had at least one of the PK concentrations for Avelumab, Utomilumab, PD 0360324, PF-04518600. Here, \"Number of participants analyzed'' signifies number of participants evaluable for this outcome measure, where \"Number Analyzed\" signifies number of participants evaluable for specified time points. For ''Phase 2 1L NSCLC: Utomilumab then Utomilumab + Avelumab'' reporting group PK sampling started from Cycle 2 Day 1.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Days 1 and 15 of Cycle 1, Day 8 of Cycle 1 (non-dosing) and then Day 1 of Cycles 2,4,6 and Cycle 10. For ''Phase 2 1L NSCLC: Utomilumab then Utomilumab + Avelumab'' reporting group: Day 1 of Cycles 2,4,6,10","title":"Pre-Dose Observed Plasma Concentration (Ctrough) of Avelumab in Combination A","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter"}